MicroRNAs for restenosis and thrombosis after vascular injury

Circulation Research

Volumn 118, Issue 7, 2016, Pages 1170-1184

  Gareri, Clarice ^a   De Rosa, Salvatore ^b   Indolfi, Ciro ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c CNR   (Italy)

Author keywords

Angioplasty; MicroRNA; Restenosis; Stent; Thrombosis; Vascular remodeling

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MICRORNA; MICRORNA 100; MICRORNA 126; MICRORNA 143; MICRORNA 145; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; UNTRANSLATED RNA; MICRORNA 125; MICRORNA 133; MICRORNA 146A; MICRORNA 195; MICRORNA 23B; MICRORNA 424; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; LONG UNTRANSLATED RNA;

BLOOD VESSEL INJURY; CELL PROLIFERATION; CELL REGENERATION; DRUG ELUTING STENT; ENDOTHELIUM; EPITHELIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTERACTIONS WITH RNA; INTRACELLULAR SIGNALING; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE CELL; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR REMODELING; CELL INTERACTION; CORONARY STENTING; DOWN REGULATION; DRUG DELIVERY SYSTEM; MICRORNA 92A; STENT; UPREGULATION; VASCULAR ENDOTHELIAL CELL; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; CELL COMMUNICATION; CELL DIVISION; CELL LINE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; INJURIES; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHENOTYPE; PHYSIOLOGY; REGENERATION; VASCULAR ENDOTHELIUM;

ANGIOPLASTY, BALLOON; ANIMALS; BIOMARKERS; CELL COMMUNICATION; CELL DIVISION; CELL LINE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; HUMANS; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; REGENERATION; RNA, LONG NONCODING; STENTS;

EID: 84976401417     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.308237     Document Type: Review

References (159)

1. Lingman M, Albertsson P, Herlitz J., Bergfeldt L, Lagerqvist B. The impact of hypertension and diabetes on outcome in patients undergoing percutaneous coronary intervention. Am J Med. 2011; 124:265-275. doi: 10.1016/j.amjmed.2010.09.015.
2. Fischman DL, Leon MB, Baim D.S., Schatz RA, Savage MP, Penn I, Detre K., Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331:496-501. doi: 10.1056/NEJM199408253310802.
3. Williams DO, Holubkov R, Yeh W., et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000; 102:2945-2951.
4. Kimura T, Abe K, Shizuta S., Odashiro K, Yoshida Y, Sakai K., Kaitani K, Inoue K, Nakagawa Y, Yokoi H, Iwabuchi M, Hamasaki N, Nosaka H, Nobuyoshi M. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002; 105:2986-2991.
5. Indolfi C, Pavia M, Angelillo IF Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol. 2005; 95:1146-1152. doi: 10.1016/j.amjcard.2005.01.040.
6. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011; 75:1287-1296.
7. Stettler C, Wandel S, Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370:937-948. doi: 10.1016/S0140-6736(07)61444-5.
8. Moussa I, Leon MB, Baim D.S., O'Neill WW, Popma JJ, Buchbinder M, Midwall J., Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004; 109:2273-2278. doi: 10.1161/01.CIR.0000129767.45513.71.
9. Stone GW, Ellis SG, Cox D.A., Hermiller J., O'Shaughnessy C, Mann JT, Turco M, Caputo R., Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004; 109:1942-1947. doi: 10.1161/01.CIR.0000127110.49192.72.
10. Lemos PA, Saia F, Ligthart J.M., et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation. 2003; 108:257-260. doi: 10.1161/01.CIR.0000083366.33686.11.
11. Colombo A, Orlic D, Stankovic G., Corvaja N, Spanos V, Montorfano M., Liistro F, Carlino M, Airoldi F, Chieffo A, Di Mario C. Preliminary observations regarding angiographic pattern of restenosis after rapamy-cin-eluting stent implantation. Circulation. 2003; 107:2178-2180. doi: 10.1161/01.CIR.0000070592.04766.36.
12. Iakovou I, Schmidt T, Ge L., Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A., Montorfano M, Carlino M, Michev I, Corvaja N, Cosgrave J, Gerckens U, Grube E, Colombo A. Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. J Am Coll Cardiol. 2005; 45:805-806. doi: 10.1016/j.jacc.2004.12.012.
13. Corbett SJ, Cosgrave J, Melzi G., Babic R, Biondi-Zoccai GG, Godino C, Morici N., Airoldi F, Michev I, Montorfano M, Sangiorgi GM, Bonizzoni E, Colombo A. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. Eur Heart J. 2006; 27:2330-2337. doi: 10.1093/eurheartj/ehl229.
14. Park CB, Hong MK, Kim Y.H., Park DW, Han KH, Lee CW, Kang D.H., Song JK, Kim JJ, Park SW, Park SJ. Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent. Int J Cardiol. 2007; 120:387-390. doi: 10.1016/j.ijcard.2006.10.014.
15. Kitahara H, Kobayashi Y, Takebayashi H., Nakamura Y, Kuroda N, Miyazaki A., Haruta S, Komuro I. Angiographic patterns of restenosis after sirolimus-eluting stent implantation. Circ J. 2009; 73:508-511.
16. Rathore S, Kinoshita Y, Terashima M., Katoh O, Matsuo H, Tanaka N., Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura K, Asakura Y, Suzuki T. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. EuroIntervention. 2010; 5:841-846.
17. Joner M, Finn AV, Farb A, Mont E.K., Kolodgie FD, Ladich E, Kutys R, Skorija K., Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48:193-202. doi: 10.1016/j.jacc.2006.03.042.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
19. Polimeni A, De Rosa S, Indolfi C. Vascular miRNAs after balloon angioplasty. Trends Cardiovasc Med. 2013; 23:9-14. doi: 10.1016/j.tcm.2012.08.004.
20. Curcio A, Torella D, Iaconetti C., Pasceri E, Sabatino J, Sorrentino S., Giampà S, Micieli M, Polimeni A, Henning BJ, Leone A, Catalucci D, Ellison GM, Condorelli G, Indolfi C. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyar-rhythmias in rodent hypertrophic hearts. PLoS One. 2013; 8:e70158. doi:10.1371/journal.pone.0070158.
21. Stellos K, Dimmeler S. Vascular microRNAs: from disease mechanisms to therapeutic targets. Circ Res. 2014; 114:3-4. doi: 10.1161/CIRCRESAHA.113.302762.
22. Rayner KJ, Moore KJ MicroRNA control of high-density lipoprotein metabolism and function. Circ Res. 2014; 114:183-192. doi: 10.1161/CIRCRESAHA.114.300645.
23. Iaconetti C, Gareri C, Polimeni A., Indolfi C. Non-coding RNAs: the "dark matter" of cardiovascular pathophysiology. Int J Mol Sci. 2013; 14:19987-20018. doi: 10.3390/ijms141019987.
24. Iaconetti C, De Rosa S, Polimeni A, Sorrentino S., Gareri C, Carino A, Sabatino J, Colangelo M, Curcio A, Indolfi C. Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 2015; 107:522-533. doi: 10.1093/cvr/cvv141.
25. De Rosa S., Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J. 2014; 78:567-575.
26. Indolfi C, Curcio A. Stargazing microRNA maps a new miR-21 star for cardiac hypertrophy. J Clin Invest. 2014; 124:1896-1898. doi: 10.1172/JCI75801.
27. Ren J, Zhang J, Xu N., Han G, Geng Q, Song J., Li S, Zhao J, Chen H. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013; 8:e80738. doi:10.1371/journal.pone.0080738.
28. Fichtlscherer S, De Rosa S, Fox H, Schwietz T., Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010; 107:677-684. doi: 10.1161/CIRCRESAHA.109.215566.
29. van Rooij E., Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014; 6:851-864. doi: 10.15252/emmm.201100899.
30. Iaconetti C, Polimeni A, Sorrentino S., Sabatino J, Pironti G, Esposito G., Curcio A, Indolfi C. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol. 2012; 107:296. doi:10.1007/s00395-012-0296-y.
31. Torella D, Iaconetti C, Catalucci D., Ellison GM, Leone A, Waring CD, Bochicchio A, Vicinanza C., Aquila I, Curcio A, Condorelli G, Indolfi C. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res. 2011; 109:880-893. doi: 10.1161/CIRCRESAHA.111.240150.
32. Hergenreider E, Heydt S, Tréguer K, Boettger T., Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis A.S., Yin X., Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012; 14:249-256. doi: 10.1038/ncb2441.
33. De Rosa S., Fichtlscherer S, Lehmann R., Assmus B, Dimmeler S, Zeiher AM Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011; 124:1936-1944. doi: 10.1161/CIRCULATIONAHA.111.037572.
34. Zhang Y, Liu D, Chen X., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010; 39:133-144. doi: 10.1016/j.molcel.2010.06.010.
35. Caporali A, Meloni M, Nailor A., Mitić T, Shantikumar S, Riu F, Sala-Newby GB, Rose L, Besnier M, Katare R, Voellenkle C, Verkade P, Martelli F, Madeddu P, Emanueli C. p75(NTR)-dependent activation of NF-κB regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia. Nat Commun. 2015; 6:8024. doi:10.1038/ncomms9024.
36. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res. 2013; 100:7-18. doi: 10.1093/cvr/cvt161.
37. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310:1137-1140. doi: 10.1056/NEJM198405033101801.
38. Plé H, Landry P, Benham A, Coarfa C, Gunaratne PH, Provost P. The repertoire and features of human platelet microRNAs. PLoS One. 2012; 7:e50746. doi:10.1371/journal.pone.0050746.
39. Diehl P, Fricke A, Sander L., Stamm J, Bassler N, Htun N., Ziemann M, Helbing T, El-Osta A, Jowett JB, Peter K. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012; 93:633-644. doi: 10.1093/cvr/cvs007.
40. Gidlöf O., van der Brug M, Ohman J, Gilje P, Olde B, Wahlestedt C, Erlinge D. Platelets activated during myocardial infarction release functional miR-NA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood. 2013; 121:3908-3917, S1. doi:10.1182/blood-2012-10-461798.
41. Indolfi C, Esposito G, Di Lorenzo E, Rapacciuolo A, Feliciello A., Porcellini A, Avvedimento VE, Condorelli M, Chiariello M. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation. 1995; 92:1230-1235.
42. Farb A, Weber DK, Kolodgie F.D., Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002; 105:2974-2980.
43. Owens GK, Kumar MS, Wamhoff BR Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004; 84:767-801. doi: 10.1152/physrev.00041.2003.
44. Sobue K, Hayashi K, Nishida W. Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation. Mol Cell Biochem. 1999; 190:105-118.
45. Indolfi C, Mongiardo A, Curcio A., Torella D. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med. 2003; 13:142-148.
46. Indolfi C, Torella D, Coppola C., Stabile E, Esposito G, Curcio A., Pisani A, Cavuto L, Arcucci O, Cireddu M, Troncone G, Chiariello M. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am J Physiol Heart Circ Physiol. 2002; 283:H760-H767. doi:10.1152/ajpheart.00613.2001.
47. Hu Y, Xu Q. Adventitial biology: differentiation and function. Arterioscler Thromb Vasc Biol. 2011; 31:1523-1529. doi: 10.1161/ATVBAHA.110.221176.
48. Li G, Chen SJ, Oparil S, Chen Y.F., Thompson JA. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000; 101:1362-1365.
49. Zengin E, Chalajour F, Gehling U.M., Ito WD, Treede H, Lauke H, Weil J., Reichenspurner H, Kilic N, Ergün S. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development. 2006; 133:1543-1551. doi: 10.1242/dev.02315.
50. Ingram DA, Mead LE, Moore D.B., Woodard W., Fenoglio A, Yoder MC. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood. 2005; 105:2783-2786. doi: 10.1182/blood-2004-08-3057.
51. Indolfi C, Chiariello M, Avvedimento EV Selective gene therapy for pro-liferative disorders: sense and antisense. Nat Med. 1996; 2:634-635.
52. Indolfi C, Coppola C, Torella D., Arcucci O, Chiariello M. Gene therapy for restenosis after balloon angioplasty and stenting. Cardiol Rev. 1999; 7:324-331.
53. Gibbons GH, Dzau VJ The emerging concept of vascular remodeling. N Engl J Med. 1994; 330:1431-1438. doi: 10.1056/NEJM199405193302008.
54. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008; 28:1950-1959. doi: 10.1161/ATVBAHA.107.161224.
55. Ji R, Cheng Y, Yue J., Yang J, Liu X, Chen H., Dean DB, Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007; 100:1579-1588. doi: 10.1161/CIRCRESAHA.106.141986.
56. Raitoharju E, Lyytikäinen LP, Levula M., Oksala N, Mennander A, Tarkka M., Klopp N, Illig T, Kähönen M, Karhunen PJ, Laaksonen R, Lehtimäki T. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011; 219:211-217. doi: 10.1016/j.atherosclerosis.2011.07.020.
57. Wang F, Zhao XQ, Liu J.N., Wang ZH, Wang XL, Hou XY, Liu R, Gao F., Zhang MX, Zhang Y, Bu PL. Antagonist of microRNA-21 improves balloon injury-induced rat iliac artery remodeling by regulating proliferation and apoptosis of adventitial fibroblasts and myofibroblasts. J Cell Biochem. 2012; 113:2989-3001. doi: 10.1002/jcb.24176.
58. Yang S, Banerjee S, Freitas A.d., Cui H., Xie N, Abraham E, Liu G. miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2012; 302:L521-L529. doi:10.1152/ajplung.00316.2011.
59. Zheng B, Han M, Wen JK Role of Krüppel-like factor 4 in phenotypic switching and proliferation of vascular smooth muscle cells. IUBMB Life. 2010; 62:132-139. doi: 10.1002/iub.298.
60. King KE, Iyemere VP, Weissberg P.L., Shanahan CM. Krüppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor beta 1 in the regulation of vascular smooth muscle cell phenotype. J Biol Chem. 2003; 278:11661-11669. doi: 10.1074/jbc.M211337200.
61. Sun SG, Zheng B, Han M., Fang XM, Li HX, Miao SB, Su M, Han Y., Shi HJ, Wen JK. miR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation. EMBO Rep. 2011; 12:56-62. doi: 10.1038/embor.2010.172.
62. Liu X, Cheng Y, Zhang S., Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009; 104:476-487. doi: 10.1161/CIRCRESAHA.108.185363.
63. Liu X, Cheng Y, Yang J., Xu L, Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012; 52:245-255. doi: 10.1016/j.yjmcc.2011.11.008.
64. Merlet E, Atassi F, Motiani R.K., Mougenot N., Jacquet A, Nadaud S, Capiod T., Trebak M, Lompré AM, Marchand A. miR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat. Cardiovasc Res. 2013; 98:458-468. doi: 10.1093/cvr/cvt045.
65. Liu Q, Fu H, Sun F., Zhang H, Tie Y, Zhu J., Xing R, Sun Z, Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008; 36:5391-5404. doi: 10.1093/nar/gkn522.
66. Aubart FC, Sassi Y, Coulombe A., Mougenot N, Vrignaud C, Leprince P., Lechat P, Lompré AM, Hulot JS. RNA interference targeting STIM1 suppresses vascular smooth muscle cell proliferation and neointima formation in the rat. Mol Ther. 2009; 17:455-462. doi: 10.1038/mt.2008.291.
67. Sahoo SK, Kim T, Kang G.B., Lee JG, Eom SH, Kim do H. Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum. J Biol Chem. 2009; 284:31109-31121. doi: 10.1074/jbc.M109.031989.
68. Luo T, Cui S, Bian C., Yu X. Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. Mol Cell Biochem. 2014; 389:169-176. doi: 10.1007/s11010-013-1938-6.
69. Ahn SM, Cha JY, Kim J, Kim D., Trang HT, Kim YM, Cho YH, Park D, Hong S. Smad3 regulates E-cadherin via miRNA-200 pathway. OncoGene. 2012; 31:3051-3059. doi: 10.1038/onc.2011.484.
70. Cordes KR, Sheehy NT, White M.P., Berry EC, Morton SU, Muth AN, Lee T.H., Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009; 460:705-710. doi: 10.1038/nature08195.
71. Xin M, Small EM, Sutherland L.B., Qi X., McAnally J, Plato CF, Richardson J.A., Bassel-Duby R, Olson EN. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009; 23:2166-2178. doi: 10.1101/gad.1842409.
72. Boucher JM, Peterson SM, Urs S, Zhang C., Liaw L. The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. J Biol Chem. 2011; 286:28312-28321. doi: 10.1074/jbc.M111.221945.
73. Cheng Y, Liu X, Yang J., Lin Y, Xu DZ, Lu Q, Deitch E.A., Huo Y., Delphin ES, Zhang C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009; 105:158-166. doi: 10.1161/CIRCRESAHA.109.197517.
74. Elia L, Quintavalle M, Zhang J., Contu R, Cossu L, Latronico M.V., Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009; 16:1590-1598. doi: 10.1038/cdd.2009.153.
75. Quintavalle M, Elia L, Condorelli G., Courtneidge SA. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol. 2010; 189:13-22. doi: 10.1083/jcb.200912096.
76. Lagna G, Ku MM, Nguyen P.H., Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem. 2007; 282:37244-37255. doi: 10.1074/jbc.M708137200.
77. ten Dijke P., Arthur HM Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007; 8:857-869. doi: 10.1038/nrm2262.
78. Wang YS, Wang HY, Liao Y.C., Tsai PC, Chen KC, Cheng HY, Lin R.T., Juo SH. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 2012; 95:517-526. doi: 10.1093/cvr/cvs223.
79. Gareri C, Sabatino J, Polimeni A., Sorrentino S, Passafaro F, Colangelo M., Covello C, Caria F, Carvelli A, Tavernese A, Carino A, Torella D, Curcio A, De Rosa S, Indolfi C. miR-125a-5p modulates the phenotypic switch of vascular smooth muscle cells by targeting ETS-1. Paper Presented at: 74° congresso nazionale Società Italiana di Cardiologia; 2013; Rome.
80. Indolfi C, Torella D, Coppola C., Curcio A, Rodriguez F, Bilancio A., Leccia A, Arcucci O, Falco M, Leosco D, Chiariello M. Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats. Circ Res. 2002; 91:1190-1197.
81. Suárez Y., Fernández-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res. 2007; 100:1164-1173. doi: 10.1161/01.RES.0000265065.26744.17.
82. Wang S, Aurora AB, Johnson B.A., Qi X., McAnally J, Hill JA, Richardson J.A., Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15:261-271. doi: 10.1016/j.devcel.2008.07.002.
83. Fish JE, Santoro MM, Morton S.U., Yu S., Yeh RF, Wythe JD, Ivey KN, Bruneau B.G., Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008; 15:272-284. doi: 10.1016/j.devcel.2008.07.008.
84. Harris TA, Yamakuchi M, Ferlito M., Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 2008; 105:1516-1521. doi: 10.1073/pnas.0707493105.
85. Zernecke A, Bidzhekov K, Noels H., Shagdarsuren E, Gan L, Denecke B., Hristov M, Köppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009; 2:ra81. doi:10.1126/scisignal.2000610.
86. Bonauer A, Carmona G, Iwasaki M., et al. MicroRNA-92a controls an-giogenesis and functional recovery of ischemic tissues in mice. Science. 2009; 324:1710-1713. doi: 10.1126/science.1174381.
87. Bonauer A, Dimmeler S. The microRNA-17-92 cluster: still a miRacle? Cell Cycle. 2009; 8:3866-3873.
88. Matsui J, Wakabayashi T, Asada M., Yoshimatsu K, Okada M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem. 2004; 279:18600-18607. doi: 10.1074/jbc.M311643200.
89. Felli N, Fontana L, Pelosi E., et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102:18081-18086. doi: 10.1073/pnas.0506216102.
90. Davis BN, Hilyard AC, Nguyen P.H., Lagna G., Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009; 284:3728-3738. doi: 10.1074/jbc.M808788200.
91. Zhu N, Zhang D, Chen S., Liu X, Lin L, Huang X., Guo Z, Liu J, Wang Y, Yuan W, Qin Y. Endothelial enriched microRNAs regulate angioten-sin II-induced endothelial inflammation and migration. Atherosclerosis. 2011; 215:286-293. doi: 10.1016/j.atherosclerosis.2010.12.024.
92. Climent M, Quintavalle M, Miragoli M., Chen J, Condorelli G, Elia L. TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ Res. 2015; 116:1753-1764. doi: 10.1161/CIRCRESAHA.116.305178.
93. Wiviott SD, Steg PG Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015; 386:292-302. doi: 10.1016/S0140-6736(15)60213-6.
94. Chyrchel B, Toton-Zuranska J, Kruszelnicka O., Chyrchel M, Mielecki W, Kolton-Wroz M, Wolkow P., Surdacki A. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets. 2014; 26:1-5. doi: 10.3109/09537104.2014.974527.
95. Valadi H, Ekström K, Bossios A., Sjöstrand M, Lee J.J., Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9:654-659. doi: 10.1038/ncb1596.
96. Vickers KC, Palmisano BT, Shoucri B.M., Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13:423-433. doi: 10.1038/ncb2210.
97. Arroyo JD, Chevillet JR, Kroh E.M., Ruf IK, Pritchard CC, Gibson DF, Mitchell P.S., Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108:5003-5008. doi: 10.1073/pnas.1019055108.
98. Turchinovich A, Weiz L, Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39:7223-7233. doi: 10.1093/nar/gkr254.
99. Wang K, Zhang S, Weber J., Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010; 38:7248-7259. doi: 10.1093/nar/gkq601.
100. Jansen F, Yang X, Baumann K., Przybilla D, Schmitz T, Flender A., Paul K, Alhusseiny A, Nickenig G, Werner N. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. J Cell Mol Med. 2015; 19:2202-2214. doi: 10.1111/jcmm.12607.
101. Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, Catherinet C., Prado-Lourenco L, Levin MG, Thacker S, Sethupathy P, Barter PJ, Remaley AT, Rye KA. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun. 2014; 5:3292. doi:10.1038/ncomms4292.
102. McManus DD, Freedman JE MicroRNAs in platelet function and cardiovascular disease. Nat Rev Cardiol. 2015; 12:711-717. doi: 10.1038/nrcardio.2015.101.
103. Bochenek G, Häsler R, El Mokhtari NE, König IR, Loos B.G., Jepsen S., Rosenstiel P, Schreiber S, Schaefer AS. The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. Hum Mol Genet. 2013; 22:4516-4527. doi: 10.1093/hmg/ddt299.
104. Bell RD, Long X, Lin M., Bergmann JH, Nanda V, Cowan SL, Zhou Q, Han Y., Spector DL, Zheng D, Miano JM. Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA. Arterioscler Thromb Vasc Biol. 2014; 34:1249-1259. doi: 10.1161/ATVBAHA.114.303240.
105. Michalik KM, You X, Manavski Y., Doddaballapur A, Zörnig M, Braun T., John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014; 114:1389-1397. doi: 10.1161/CIRCRESAHA.114.303265.
106. Fiedler J, Breckwoldt K, Remmele C.W., Hartmann D., Dittrich M, Pfanne A, Just A., Xiao K, Kunz M, Müller T, Hansen A, Geffers R, Dandekar T, Eschenhagen T, Thum T. Development of long noncoding RNA-based strategies to modulate tissue vascularization. J Am Coll Cardiol. 2015; 66:2005-2015. doi: 10.1016/j.jacc.2015.07.081.
107. Memczak S, Jens M, Elefsinioti A., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013; 495:333-338. doi: 10.1038/nature11928.
108. Hansen TB, Jensen TI, Clausen B.H., Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495:384-388. doi: 10.1038/nature11993.
109. van Rooij E. Introduction to the series on microRNAs in the cardiovascular system. Circ Res. 2012; 110:481-482. doi: 10.1161/CIRCRESAHA.111.257311.
110. Corsten MF, Dennert R, Jochems S., Kuznetsova T, Devaux Y, Hofstra L., Wagner DR, Staessen JA, Heymans S, Schroen B. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010; 3:499-506. doi: 10.1161/CIRCGENETICS.110.957415.
111. He M, Gong Y, Shi J., et al. Plasma microRNAs as potential noninva-sive biomarkers for in-stent restenosis. PLoS One. 2014; 9:e112043. doi:10.1371/journal.pone.0112043.
112. Landry P, Plante I, Ouellet D.L., Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009; 16:961-966. doi: 10.1038/nsmb.1651.
113. Chesnutt JK, Han HC Simulation of the microscopic process during initiation of stent thrombosis. Comput Biol Med. 2015; 56:182-191. doi: 10.1016/j.compbiomed.2014.11.006.
114. Bonello L, Sabatier F, Camoin-Jau L, Paganelli F., Dignat-George F. Platelets and endothelium: two key players in percutaneous coronary intervention. Arch Cardiovasc Dis. 2011; 104:601-603. doi: 10.1016/j.acvd.2011.10.003.
115. Cirillo P, Golino P, Calabrò P, Ragni M, Forte L, Piro O, De Rosa S, Pacileo M, Chiariello M. Activated platelets stimulate tissue factor expression in smooth muscle cells. Thromb Res. 2003; 112:51-57. doi: 10.1016/j.thromres.2003.11.011.
116. Edelstein LC, Bray PF MicroRNAs in platelet production and activation. Blood. 2011; 117:5289-5296. doi: 10.1182/blood-2011-01-292011.
117. Nagalla S, Shaw C, Kong X., Kondkar AA, Edelstein LC, Ma L, Chen J., McKnight GS, López JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011; 117:5189-5197. doi: 10.1182/blood-2010-09-299719.
118. Kondkar AA, Bray MS, Leal S.M., Nagalla S., Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart S.W., Shaw C., Bray PF. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost. 2010; 8:369-378. doi: 10.1111/j.1538-7836.2009.03700.x.
119. ∗. PLoS One. 2011; 6:e25946. doi:10.1371/journal.pone.0025946.
120. de Planell-Saguer M, Rodicio MC. Detection methods for microRNAs in clinic practice. Clin Biochem. 2013; 46:869-878. doi: 10.1016/j.clinbiochem.2013.02.017.
121. Moltzahn F, Olshen AB, Baehner L, Peek A., Fong L, Stöppler H, Simko J., Hilton JF, Carroll P, Blelloch R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011; 71:550-560. doi: 10.1158/0008-5472.CAN-10-1229.
122. Shingara J, Keiger K, Shelton J., Laosinchai-Wolf W, Powers P, Conrad R., Brown D, Labourier E. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA. 2005; 11:1461-1470. doi: 10.1261/rna.2610405.
123. Jiang L, Duan D, Shen Y., Li J. Direct microRNA detection with universal tagged probe and time-resolved fluorescence technology. Biosens Bioelectron. 2012; 34:291-295. doi: 10.1016/j.bios.2012.01.035.
124. Sun Y, Gregory KJ, Chen N.G., Golovlev V. Rapid and direct microR-NA quantification by an enzymatic luminescence assay. Anal Biochem. 2012; 429:11-17. doi: 10.1016/j.ab.2012.06.021.
125. Nelson PT, Baldwin DA, Kloosterman W.P., Kauppinen S., Plasterk RH, Mourelatos Z. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2006; 12:187-191. doi: 10.1261/rna.2258506.
126. Driskell JD, Seto AG, Jones L.P., Jokela S., Dluhy RA, Zhao YP, Tripp RA. Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS). Biosens Bioelectron. 2008; 24:923-928. doi: 10.1016/j.bios.2008.07.060.
127. Dorvel BR, Reddy B Jr, Go J, Duarte Guevara C, Salm E, Alam M.A., Bashir R. Silicon nanowires with high-k hafnium oxide dielectrics for sensitive detection of small nucleic acid oligomers. ACS Nano. 2012; 6:6150-6164. doi: 10.1021/nn301495k.
128. Cutlip DE. Stent thrombosis: historical perspectives and current trends. J Thromb Thrombolysis. 2000; 10:89-101.
129. Lanford RE, Hildebrandt-Eriksen ES, Petri A., Persson R, Lindow M, Munk M.E., Kauppinen S., Ørum H. Therapeutic silencing of microR-NA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327:198-201. doi: 10.1126/science.1178178.
130. Pullamsetti SS, Doebele C, Fischer A., Savai R, Kojonazarov B, Dahal B.K., Ghofrani HA, Weissmann N, Grimminger F, Bonauer A, Seeger W, Zeiher AM, Dimmeler S, Schermuly RT. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2012; 185:409-419. doi: 10.1164/rccm.201106-1093OC.
131. McDonald RA, Halliday CA, Miller A.M., Diver LA, Dakin RS, Montgomery J, McBride M.W., Kennedy S., McClure JD, Robertson KE, Douglas G, Channon KM, Oldroyd KG, Baker AH. Reducing in-stent restenosis: therapeutic manipulation of miRNA in vascular remodeling and inflammation. J Am Coll Cardiol. 2015; 65:2314-2327. doi: 10.1016/j.jacc.2015.03.549.
132. Santulli G, Wronska A, Uryu K., Diacovo TG, Gao M, Marx SO, Kitajewski J, Chilton J.M., Akat KM, Tuschl T, Marks AR, Totary-Jain H. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014; 124:4102-4114. doi: 10.1172/JCI76069.
133. Wang D, Deuse T, Stubbendorff M., et al. Local MicroRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol. 2015; 35:1945-1953. doi: 10.1161/ATVBAHA.115.305597.
134. Indolfi L, Causa F, Giovino C., Ungaro F, Quaglia F, Netti PA Microsphere-integrated drug-eluting stents: PLGA microsphere integration in hydrogel coating for local and prolonged delivery of hydrophilic antirestenosis agents. J Biomed Mater ReS A. 2011; 97:201-211. doi: 10.1002/jbm.a.33039.
135. Pironti G, Strachan RT, Abraham D, Mon-Wei Yu S, Chen M, Chen W, Hanada K, Mao L, Watson LJ, Rockman HA. Circulating exosomes induced by cardiac pressure overload contain functional angiotensin II type 1 receptors. Circulation. 2015; 131:2120-2130. doi: 10.1161/CIRCULATIONAHA.115.015687.
136. Sahoo S, Losordo DW Exosomes and cardiac repair after myo-cardial infarction. Circ Res. 2014; 114:333-344. doi: 10.1161/CIRCRESAHA.114.300639.
137. Sluijter JP, Verhage V, Deddens J.C., van den Akker F, Doevendans PA. Microvesicles and exosomes for intracardiac communication. Cardiovasc Res. 2014; 102:302-311. doi: 10.1093/cvr/cvu022.
138. Iaconetti C, Sorrentino S, De Rosa S, Indolfi C. Exosomal miRNAs in heart disease. Physiology (Bethesda). 2016; 31:16-24. doi: 10.1152/physiol.00029.2015.
139. Kovacs EW, Hooker JM, Romanini D.W., Holder PG, Berry KE, Francis MB. Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjug Chem. 2007; 18:1140-1147. doi: 10.1021/bc070006e.
140. Rodríguez-Limas W.A., Sekar K, Tyo KE Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development. Curr Opin Biotechnol. 2013; 24:1089-1093. doi: 10.1016/j.copbio.2013.02.008.
141. Pan Y, Jia T, Zhang Y., Zhang K, Zhang R, Li J., Wang L. MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int J Nanomedicine. 2012; 7:5957-5967. doi: 10.2147/IJN.S37990.
142. Pan Y, Zhang Y, Jia T., Zhang K, Li J, Wang L. Development of a microR-NA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 2012; 279:1198-1208. doi: 10.1111/j.1742-4658.2012.08512.x.
143. Sun CY, She XM, Qin Y, Chu Z.B., Chen L., Ai LS, Zhang L, Hu Y. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 2013; 34:426-435. doi: 10.1093/carcin/bgs333.
144. Josse C, Bouznad N, Geurts P., Irrthum A, Huynh-Thu VA, Servais L, Hego A., Delvenne P, Bours V, Oury C. Identification of a microRNA landscape targeting the PI3K/Akt signaling pathway in inflammation-induced colorectal carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2014; 306:G229-G243. doi:10.1152/ajpgi.00484.2012.
145. Haug BH, Henriksen JR, Buechner J, Geerts D., Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B, Einvik C. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis. 2011; 32:1005-1012. doi: 10.1093/carcin/bgr073.
146. Liu YX, Long XD, Xi Z.F., Ma Y., Huang XY, Yao JG, Wang C, Xing T.Y., Xia Q. MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int. 2014; 2014:482926. doi:10.1155/2014/482926.
147. Li X, Liu X, Xu W., Zhou P, Gao P, Jiang S., Lobie PE, Zhu T. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem. 2013; 288:18121-18133. doi: 10.1074/jbc.M113.478560.
148. O'Kelly F., Marignol L, Meunier A., Lynch TH, Perry AS, Hollywood D. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol. 2012; 9:397-407. doi: 10.1038/nrurol.2012.104.
149. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol. 2007; 27:1248-1258. doi: 10.1161/ATVBAHA.107.141069.
150. Pfaltzgraff ER, Shelton EL, Galindo C.L., Nelms BL, Hooper CW, Poole SD, Labosky P.A., Bader DM, Reese J. Embryonic domains of the aorta derived from diverse origins exhibit distinct properties that converge into a common phenotype in the adult. J Mol Cell Cardiol. 2014; 69:88-96. doi: 10.1016/j.yjmcc.2014.01.016.
151. Zhang H, Gu S, Al-Sabeq B, Wang S., He J, Tam A, Cifelli C., Mathalone N, Tirgari S, Boyd S, Heximer SP. Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression. FASEB J. 2012; 26:181-191. doi: 10.1096/fj.11-185454.
152. Rajabi M, Kassiotis C, Razeghi P., Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev. 2007; 12:331-343. doi: 10.1007/s10741-007-9034-1.
153. Oka T, Xu J, Molkentin JD Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol. 2007; 18:117-131. doi: 10.1016/j.semcdb.2006.11.012.
154. Jiang YS, Jiang T, Huang B., Chen PS, Ouyang J. Epithelial-mesenchymal transition of renal tubules: divergent processes of repairing in acute or chronic injury? Med Hypotheses. 2013; 81:73-75. doi: 10.1016/j.mehy.2013.03.020.
155. Slottow TL, Waksman R. Drug-eluting stent safety. Am J Cardiol. 2007; 100:10M-17M. doi:10.1016/j.amjcard.2007.08.017.
156. Capodanno D, Gori T, Nef H., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10:1144-1153. doi: 10.4244/EIJY14M07-11.
157. Ellis SG, Kereiakes DJ, Metzger D.C., Caputo RP, Rizik DG, Teirstein PS, Litt M.R., Kini A., Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015; 373:1905-1915. doi: 10.1056/NEJMoa1509038.
158. Kimura T, Kozuma K, Tanabe K., et al; ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015; 36:3332-3342. doi: 10.1093/eurheartj/ehv435.
159. Gao R, Yang Y, Han Y., et al; ABSORB China Investigators. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol. 2015; 66:2298-2309. doi: 10.1016/j.jacc.2015.09.054.